.Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04B_Urologicals.G04BD11_Fesoterodine.Fesoterodine

Information

Fesoterodine is an antimuscarinic agent used for the treatment of overactive bladder with symptoms of urinary frequency, urgency, and urge incontinence. It is an approved oral medication active as a prodrug, rapidly converted to its active metabolite 5-hydroxymethyl tolterodine (5-HMT).

Pharmacokinetics

Pharmacokinetic parameters of fesoterodine (as its active metabolite 5-HMT) were characterized in healthy adult subjects (male and female, age 18-55) after administration of the recommended 8 mg oral dose in the fasted state.

References

1. Oishi, M, et al., & Malhotra, B (2014). Population pharmacokinetics of the 5-hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in Western and East Asian populations. Journal of clinical pharmacology 54(8) 928–936. DOI:10.1002/jcph.274 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24619889

2. Malhotra, BK, et al., & Sachse, R (2009). Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. International journal of clinical pharmacology and therapeutics 47(9) 570–578. DOI:10.5414/cpp47570 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19761716

3. Kitta, T, et al., & Crook, TJ (2023). Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study. Journal of pediatric urology 19(2) 175.e1–175.e10. DOI:10.1016/j.jpurol.2022.11.020 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36504158

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)